TRC-PAD Program: In-Clinic Trial-Ready Cohort

Completed

Conditions studied: Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia

In brief

The purpose of the TRC-PAD study is to develop a large, well-characterized, biomarker-confirmed, trial-ready cohort to facilitate rapid enrollment into AD prevention trials utilizing the APT Webstudy and subsequent referral to in-clinic evaluation and biomarker confirmation. Participants with known biomarker status may have direct referral to the Trial-Ready Cohort. If you are interested in being selected for the TRC-PAD study, you should first enroll in the APT Webstudy (https://www.aptwebstudy.org/welcome).

Key facts

Study ID

NCT04004767

Run by

University of Southern California

People needed

220

Starts

2019-06-04

Expected to finish

2024-04-01

Last updated by the study team

2024-06-27

Who can join

Age: 50 and older, up to 85. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Provision of signed and dated informed consent form
• Stated availability and willingness to comply with all study procedures until referred to a clinical trial
• Age 50-85 (inclusive)
• Global Clinical Dementia Rating (CDR) score of 0 or 0.5 and no diagnosis of dementia
• Has a study partner that is willing to participate as a source of information and has at least weekly contact with the participant (contact can be in-person, via telephone or electronic communication). The study partner must have sufficient contact such that the investigator feels the study partner can provide meaningful information about the participant's daily function.
• In good general health as evidenced by medical history
• Adequate visual and auditory acuity to allow neuropsychological testing
• Fluent in English or Spanish
• For females who are not surgically sterile or post-menopausal by two years, receiving a Positron Emission Tomography (PET) scan for amyloid biomarker confirmation: negative pregnancy test prior to amyloid PET scan
• Completed six grades of education or has a good work history
• Evidence of elevated or intermediate (subthreshold) levels brain amyloid as assessed by central review of amyloid PET or cerebrospinal fluid (CSF) data. Prior amyloid testing results may be used with approval from the Coordinating Center.

You may not qualify if…

• Treatment with an another anti-amyloid investigational anti-amyloid drug or other experimental intervention within 12 months. Use of aducanumab or other approved anti-amyloid treatments allowed if stable for at least 3 months.
• Enrolled in another interventional clinical trial within the last 12 weeks
• Any significant neurologic disease such as Alzheimer's disease dementia, Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities.
• Major depression, bipolar disorder as described in DSM-V within the past 1 year or psychotic features, agitation or behavioral problems within 3 months, which could lead to difficulty complying with the protocol
• History of schizophrenia (DSM V criteria)
• History of alcohol or substance abuse or dependence within the past 2 years (DSM V criteria)
• Clinically significant or unstable medical condition, including uncontrolled hypertension, uncontrolled diabetes, or significant cardiac, pulmonary, renal, hepatic, endocrine, or other systemic disease in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or influence the results, or the participant's ability to participate in the study.
• History within the last 3 years of a primary or recurrent malignant disease with the exception of non-melanoma skin cancers, resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with normal prostate-specific antigen post-treatment
• Clinically significant abnormalities in B12 or thyroid function tests (TFTs) that might interfere with the study. A low B12 is exclusionary, unless follow-up labs (homocysteine (HC) and methylmalonic acid (MMA)) indicate that it is not physiologically significant.
• Clinically significant abnormalities in screening laboratories or ECG.
• For participants undergoing CSF collection: a current blood clotting or bleeding disorder, or significantly abnormal PT or PTT at screening or if on anti-coagulation (e.g. warfarin)
• Participants whom the Site PI deems to be otherwise ineligible.

Where it is running

• University of Alabama — Birmingham, Alabama, United States
• Banner Alzheimer's Institute — Phoenix, Arizona, United States
• Banner Sun Health Research Institute — Sun City, Arizona, United States
• University of California, Irvine — Irvine, California, United States
• University of Southern California — Los Angeles, California, United States
• Yale University — New Haven, Connecticut, United States
• Georgetown University — Washington D.C., District of Columbia, United States
• Brain Matters Research — Delray Beach, Florida, United States
• Mayo Clinic Jacksonville — Jacksonville, Florida, United States
• Gonzalez MD & Aswad MD Health Services — Miami, Florida, United States
• Wien Center for Alzheimer's Disease — Miami Beach, Florida, United States
• Renstar Medical Research — Ocala, Florida, United States
• Synexus Clinical Research Orlando — Orlando, Florida, United States
• University of South Florida - Health Byrd Alzheimer Institute — Tampa, Florida, United States
• Synexus Clinical Research, The Villages — The Villages, Florida, United States
• Charter Research, LLC — Winter Park, Florida, United States
• Northwestern University — Chicago, Illinois, United States
• Rush University — Chicago, Illinois, United States
• Indiana University — Indianapolis, Indiana, United States
• University of Kansas — Fairway, Kansas, United States
• University of Kentucky — Lexington, Kentucky, United States
• Johns Hopkins University — Baltimore, Maryland, United States
• Brigham & Women's Hospital — Boston, Massachusetts, United States
• Headlands Eastern MA LLC — Plymouth, Massachusetts, United States
• University of Michigan — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.